







# Embarc Benefit Protection®



FDA Approved	Therapy Name and Disease	Therapy Description	Embarc Inclusion Date*	Contractual Limitations
2025	 <b>Waskyra™</b> Wiskott-Aldrich syndrome (WAS)	Autologous hematopoietic stem cell-based gene therapy administered via one-time IV infusion in patients six months and older	7/1/2026	Financial protection applies when medical necessity review requests are received after the Embarc Inclusion Date for employers actively enrolled in Embarc Benefit Protection.
2025	 <b>Encelto™</b> Macular telangiectasia type 2 (MacTel)	Encapsulated cell-based gene therapy administered via one-time surgical implantation into the eye	7/1/2026	Financial protection applies when medical necessity review requests are received after the Embarc Inclusion Date for employers actively enrolled in Embarc Benefit Protection.
2025	 <b>Itvisma®</b> Spinal Muscular Atrophy (SMA)	For children 2 years of age and older with a confirmed mutation in the SMN1 gene. Viral vector gene therapy administered via a one-time intrathecal injection	7/1/2026	Financial protection applies when medical necessity review requests are received after the Embarc Inclusion Date for employers actively enrolled in Embarc Benefit Protection.
2024	 <b>Elevidys®</b> Duchenne muscular dystrophy (DMD)	Elevidys is an adeno-associated virus vector-based gene therapy indicated for the treatment of patients 4 years of age or older who are ambulatory and have a confirmed mutation of the DMD gene	7/1/2026	Financial protection applies when medical necessity review requests are received after the Embarc Inclusion Date for employers actively enrolled in Embarc Benefit Protection.
2024	 <b>Kebilidi™</b> Aromatic L-Amino Acid Decarboxylase (AADC) Deficiency	Aims to correct the genetic cause of AADC deficiency, a rare nervous system disorder causing problems with motor control, muscle weakness, and delayed development	7/1/2025	Financial protection applies when medical necessity review requests are received after the Embarc Inclusion Date for employers actively enrolled in Embarc Benefit Protection.
2024	 <b>Lenmeldy™</b> Metachromatic leukodystrophy	For the treatment of a rare disease that affects the brains and nervous	8/1/2024	Financial protection applies when medical necessity review requests are received after the Embarc Inclusion

Therapy Classes

-  Oncology
-  Cardiovascular
-  Hematology
-  Rheumatology
-  Transplant
-  Metabolic Disorders
-  Diabetes
-  Ophthalmology
-  Immunology
-  Dermatology
-  Neurology
-  Genetic Disorders

# Embarc Benefit Protection®




			systems of children in their late infantile and early juvenile years		Date for employers actively enrolled in Embarc Benefit Protection.
2024		<b>Casgevy®</b> Beta-thalassemia	Used for a blood disorder known as beta-thalassemia in patients who cannot make enough beta-globin and require regular blood transfusions	4/1/2024	For existing Embarc Benefit Protection clients with effective dates of April 1, 2024 or earlier, all customers who meet the solution’s clinical and network criteria for Casgevy (for the treatment of sickle cell disease) will be able to access the therapy through Embarc Benefit Protection. For clients who join Embarc Benefit Protection after April 1, 2024, the financial protection extends only to customers who join the underlying medical coverage 30 days or more after the client is effective in Embarc Benefit Protection. No longer in effect as of 7/1/2026.  Financial protection applies when medical necessity review requests are received after the Embarc Inclusion Date for employers actively enrolled in Embarc Benefit Protection.
2023		<b>Casgevy®</b> Sickle cell disease	For the treatment of sickle cell disease (SCD) - an inherited blood disorder where red blood cells become hard, sticky, and shaped like a sickle. These misshapen cells block blood flow, causing pain, anemia, and organ damage. It’s lifelong but manageable	4/1/2024	For existing Embarc Benefit Protection clients with effective dates of April 1, 2024 or earlier, all customers who meet the solution’s clinical and network criteria for Casgevy (for the treatment of sickle cell disease) will be able to access the therapy through Embarc

Therapy Classes

- Oncology
- Cardiovascular
- Hematology
- Rheumatology
- Transplant
- Metabolic Disorders
- Diabetes
- Ophthalmology
- Immunology
- Dermatology
- Neurology
- Genetic Disorders

# Embarc Benefit Protection®



			with treatment in patients 12 years and older with recurrent vaso-occlusive crises (VOCs)		Benefit Protection. For clients who join Embarc Benefit Protection after April 1, 2024, the financial protection extends only to customers who join the underlying medical coverage 30 days or more after the client is effective in Embarc Benefit Protection. No longer in effect as of 7/1/2026.  Financial protection applies when medical necessity review requests are received after the Embarc Inclusion Date for employers actively enrolled in Embarc Benefit Protection.
2023		<b>Lyfgenia™</b> Sickle cell disease	For the treatment of sickle cell disease (SCD) - an inherited blood disorder where red blood cells become hard, sticky, and shaped like a sickle. These misshapen cells block blood flow, causing pain, anemia, and organ damage. It's lifelong but manageable with treatment in patients 12 years and older with recurrent vaso-occlusive crises (VOCs)	4/1/2024	For existing Embarc Benefit Protection clients with effective dates of April 1, 2024 or earlier, all customers who meet the solution's clinical and network criteria for Lyfgenia will be able to access the therapy through Embarc Benefit Protection. For clients who join Embarc Benefit Protection after April 1, 2024, the financial protection extends only to customers who join the underlying medical coverage 30 days or more after the client is effective in Embarc Benefit Protection. No longer in effect as of 7/1/2026.  Financial protection applies when medical necessity review requests are

Therapy Classes

-  Oncology
-  Cardiovascular
-  Hematology
-  Rheumatology
-  Transplant
-  Metabolic Disorders
-  Diabetes
-  Ophthalmology
-  Immunology
-  Dermatology
-  Neurology
-  Genetic Disorders

# Embarc Benefit Protection®





					received after the Embarc Inclusion Date for employers actively enrolled in Embarc Benefit Protection.
2023		<b>Roctavian®</b> Hemophilia A	A gene therapy from BioMarin for the treatment of adults with severe Hemophilia A, with factor VIII activity less than 1 IU/dL, who are without pre-existing antibodies to adeno-associated virus serotype 5 (detected by an FDA-approved test)	9/1/2023	Financial protection applies when medical necessity review requests are received after the Embarc Inclusion Date for employers actively enrolled in Embarc Benefit Protection.
2022		<b>Hemgenix®</b> Hemophilia B	For the treatment of adults with Hemophilia B (congenital Factor IX deficiency) who currently use Factor IX prophylaxis therapy, or have current or historical life-threatening hemorrhage, or have repeated, serious spontaneous bleeding episodes	3/1/2023	Financial protection applies when medical necessity review requests are received after the Embarc Inclusion Date for employers actively enrolled in Embarc Benefit Protection.
2022		<b>Skysona™</b> Adrenoleukodystrophy	To slow the progress of neurologic dysfunction in boys 4-17 years of age with early, active cerebral adrenoleukodystrophy (CALD)	12/1/2022	Financial protection applies when medical necessity review requests are received after the Embarc Inclusion Date for employers actively enrolled in Embarc Benefit Protection.
2022		<b>Zynteglo™</b> Beta-thalassemia	Used for a blood disorder known as beta-thalassemia in patients who cannot make enough beta-globin and require regular blood transfusions	8/1/2022	Financial protection applies when medical necessity review requests are received after the Embarc Inclusion Date for employers actively enrolled in Embarc Benefit Protection.

Therapy Classes

- Oncology
- Cardiovascular
- Hematology
- Rheumatology
- Transplant
- Metabolic Disorders
- Diabetes
- Ophthalmology
- Immunology
- Dermatology
- Neurology
- Genetic Disorders






# Embarc Benefit Protection®



2019		<b>Zolgensma®</b> Spinal Muscular Atrophy (SMA)	A gene therapy for children under two years of age with spinal muscular atrophy	7/1/2020	<p>The financial protection against the high cost of Zolgensma applies only to children born after the Embarc Benefit Protection solution is effective for their group health plan. No longer in effect as of 7/1/2026.</p> <p>Financial protection applies when medical necessity review requests are received after the Embarc Inclusion Date for employers actively enrolled in Embarc Benefit Protection.</p>
2017		<b>Luxturna®</b> Retinal Dystrophy	The first FDA-approved prescription gene therapy for people with inherited retinal disease	7/1/2020	<p>Financial protection applies when medical necessity review requests are received after the Embarc Inclusion Date for employers actively enrolled in Embarc Benefit Protection.</p>

\*Embarc Inclusion Date is, for each Embarc gene therapy, the date that such Embarc gene therapy is made a part of the Embarc Services. Financial protection applies when medical necessity review requests are received after the Embarc Inclusion Date for employers actively enrolled in Embarc Benefit Protection.

**Therapy Classes**

-  Oncology
-  Cardiovascular
-  Hematology
-  Rheumatology
-  Transplant
-  Metabolic Disorders
-  Diabetes
-  Ophthalmology
-  Immunology
-  Dermatology
-  Neurology
-  Genetic Disorders